Pneumococcal

The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).

Cefiderocol approved for the treatment with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Two phase 3 studies showed an investigational 15-valent pneumococcal conjugate vaccine (V114, Merck) was well-tolerated among patients and met the primary immunogenicity objectives.

Overtreatment of acute cough can help reduce antibiotic use.

Patients can be aided by health care providers with preventable measures to reduce the chance of infectious risk.

Results from 2 initial phase 3 studies evaluating an investigational 15-valent pneumococcal conjugate vaccine were recently released, assessing its immunogenicity, safety, and tolerability.

The combination of imipenem-cilastatin and relebactam was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.

This will be the first global study of tocilizumab in this setting and is expected to begin enrolling in early April, with a target of approximately 330 patients globally.

The FDA has approved Xenleta (Lefamulin, from Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

Pharmacists play a critical role in protecting patients from seasonal influenza and pneumonia illnesses and sequelae.

These 5 developments, including epidemic forecasting and inhaled antibiotics to treat pneumonia, have global research behind them.

The NFID released data that revealed only 52% of adults in the country plan to get vaccinated against the flu this season.

What is causing the oliguria in this normally healthy young man with a history of acne and a current sinus infection?

Meningitis is a deadly condition that affects up to 1 million people per year globally.1

According to the World Health Organization, 240 vaccines were in development for 25 infectious diseases.5 Topping the list for most candidate vac- cines are HIV/AIDS, malaria, pneumococcal infec- tions, tuberculosis, and Ebola.

The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.

A new study published in the Annals of Internal Medicine this week suggests that opioids may pose a different, unintended untoward consequence in patients: an increased risk of pneumococcal infection.

Streptococcus pneumoniae (pneumococcus) infects approximately 4 million Americans annually. As a result of this infection, there are approximately 445,000 hospitalizations and 22,000 deaths in the United States each year.

Researchers explore the impact of pneumococcal vaccines and antibiotic usage on trends in colonization in young, healthy children.

Sixty-seven million at-risk Americans remain unvaccinated for pneumococcal disease

People with work-related asthma are particularly vulnerable to pneumococcal pneumonia.

This initiative emphasizes the importance of early recognition and timely treatment of sepsis, as well as the importance of preventing infections that could lead to sepsis.

Treatment with verapamil successfully improved symptoms of chronic rhinosinusitis with nasal polyps.